What is CVE-2022-26239?

CVE-2022-26239 is a medium-severity vulnerability in Beckmancoulter Remisol Advance, classified under Incorrect Permission Assignment for Critical Resource. CVSS score: 5.5/10. Published 2022-10-06.

How severe is CVE-2022-26239?

Medium severity. CVSS v3 base score is 5.5 out of 10.

Vulnerability in Beckmancoulter Remisol Advance

CVE-2022-26239

The default privileges for the running service Normand License Manager in Beckman Coulter Remisol Advance v2.0.12.1 and prior allows unprivileged users to overwrite and manipulate executables and libraries. This allows attackers to access sensitive data.

Published 2022-10-06 · last modified 2026-06-17.

CVSS v3 metric

CVSS v3 base score 5.5 (Medium). Vector: CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N.

EPSS exploit prediction

EPSS: 0.002 (10.7th percentile), scored 2026-10-01.

Very low probability of exploitation in the next 30 days; routine patching cadence is appropriate. 11th percentile — 10.7% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.

EPSS over last 30 days · oldest: 0.002 · newest: 0.002 · change: +0.000

Affected products

Weakness classification (CWE)

CWE-732 — Incorrect Permission Assignment for Critical Resource

References

www.beckmancoulter.com/products/clinical-information-management-tools/remisol-a… (Product)
pastebin.com/1QEHrj01 (Third Party Advisory)

Frequently asked questions

What is CVE-2022-26239?: CVE-2022-26239 is a medium-severity vulnerability in Beckmancoulter Remisol Advance, classified under Incorrect Permission Assignment for Critical Resource. CVSS score: 5.5/10. Published 2022-10-06.
How severe is CVE-2022-26239?: Medium severity. CVSS v3 base score is 5.5 out of 10.